The Actinogen Medical Ltd (ASX: ACW) share price jumped 4.5% on open this morning, after the company announced it has filed two new patent applications to strengthen and extend its intellectual property (IP) portfolio.
What does Actinogen Medical do?
Actinogen Medical is an ASX biotech company. It specialises in developing novel therapies of a range of conditions. These include neurological, psychiatric and metabolic diseases associated with chronically elevated cortisol. This is a metabolic disorder caused by overproduction of corticosteroid hormones by the adrenal cortex. Often it is associated with obesity and high blood pressure.
The lead compound currently being developed by Actinogen is called “Xanamem”. This compound is a new type of therapy for Alzheimer’s disease, Fragile X syndrome, schizophrenia and diabetes. According to the company, solutions to effectively address these conditions and the burdens for patients have not yet adequately been met. It is therefore focusing on the gap in this market.
Why are these patents important?
The two patents filed this week are to expand and extend the company’s IP estate.
The first patent filed requests protection for a method of improving cognition or treating cognitive decline in cognitively healthy subjects. Expansion of the IP estate is a key goal here.
The second patent filed provided protection to a commercial scale-up manufacturing process for Xanamem. This patent is the result of a collaborative effort between Actinogen Medical and a Switzerland-based contract development and manufacturing organisation.
Actinogen holds a large number of patents, either granted or pending. The new patents filed this week have the ability to extend patent life. Protection around Xanamem is now effective until 2040 at least. This gives the company a long runway of breathing room to continue its research and development.
In statement to the ASX today, Actinogen Medical CEO and managing director Dr Bill Ketelbey had this to say:
Strengthening our IP portfolio and extending the patent life of protection over Xanamem is aligned with our broader commercialisation strategy for Xanamem. The potential to treat cognitively healthy subjects, a population in which XanaHES demonstrated clear efficacy results, as well as treat those at risk of cognitive impairment, is a significant medical and commercial opportunity. Equally, the patented and optimised manufacturing methodology provides an efficient and commercially viable process which provides a substantial new barrier to competition. Actinogen remains focused on maintaining and extending the protection of Xanamem to maximise its commercial potential.
The Actinogen Medical share price opened 4.5% higher on this positive news today. However, overall this year the Actinogen Medical share price is down more than 30%.
If there's one thing for sure, 2020 has been the year we embraced sanitisation. Scott Phillips has discovered a little-known Australian healthcare company could be set to reap the rewards of the post-covid world.
Better yet, this fast-growing company is currently trading at a 30% discount from its highs. Scott believes in this stock so much, he's staked $209k of our own company money on it. Forget 'buy now pay later', this stock could be the next hot stock on the ASX.
Scott and his team have published a detailed report on this tiny ASX stock. Find out how you can access our TOP healthcare stock today!
As of 2.11.2020
Motley Fool contributor glennleese has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- AI-Media (ASX:AIM) share price is up 3% on US acquisitions update – December 14, 2020 1:47pm
- What is a holding company? – November 30, 2020 2:52pm
- PayGroup (ASX:PYG) share price rocky following half year results – November 24, 2020 1:32pm